Beyond Air Inc. (NASDAQ: XAIR) Drives 107 % Revenue Surge in FY 2026

Beyond Air Inc. reported a dramatic 107 % year‑over‑year increase in fiscal 2026 revenue, reaching $7.7 million compared with $3.7 million in the prior year. The company’s fourth‑quarter performance mirrored this momentum, posting $1.9 million in sales—an 66 % rise from the same period in 2025. These figures underscore Beyond Air’s accelerating commercial traction in its niche of nitric‑oxide‑based therapeutics for respiratory disease.

Gross Profit Turn‑Around and Cost Discipline

A pivotal highlight of the fiscal year was the shift to positive gross profit. For the full year, Beyond Air generated $0.3 million in gross profit, a turnaround from a gross‑loss in 2025. The improvement stemmed from a 39 % reduction in R&D expenses to $10.2 million and a 27 % drop in SG&A to $19.1 million. By tightening cost structure while expanding sales, the company has moved closer to profitability, a trend that will likely continue as revenue scales.

Cash Position and Capital Strategy

The company closed FY 2026 with $17.3 million in cash and securities, a modest decline from the $19.1 million balance at the end of 2025. Nevertheless, the cash runway remains sufficient to support ongoing product development and commercialization. In line with shareholder value creation, Beyond Air approved a 1‑for‑20 reverse stock split, a common practice for companies seeking to lift share price and improve liquidity after sustained low trading levels.

Guidance and Outlook

Beyond Air has issued forward guidance for the upcoming fiscal year ending December 31 2026, projecting revenue of $8 million—an approximate 15 % increase from the current year. For FY 2027, management forecasts $16‑$18 million or more than 110 % growth, reflecting confidence in expanding product pipelines and market penetration.

The company’s strategic shift to a December 31 year‑end aligns better with the broader U.S. healthcare calendar, potentially smoothing seasonal sales fluctuations and enhancing comparability with peers.

Market Implications

  • Stock Price: Following the announcement, XAIR’s share price remained near the $0.50 level, reflecting the company’s still‑nascent scale and the broader market’s caution toward high‑growth, high‑loss biopharma firms.
  • Valuation: With a market cap of $6.08 million and a negative P/E of ‑0.088, the valuation remains heavily discounted. The recent revenue acceleration, however, could justify a re‑assessment once profitability is achieved.
  • Investment Thesis: For investors focused on high‑potential, low‑valuation biotech assets, Beyond Air presents a compelling case. The company’s unique nitric‑oxide technology, coupled with a clear path to revenue growth and cost efficiency, positions it to capture significant market share in the respiratory therapeutics space.

Forward‑Looking Statements

Beyond Air’s leadership emphasized that continued investment in research and regulatory milestones will be essential to sustain growth. While the company has shown impressive revenue gains, it acknowledges that achieving sustained profitability will require further commercialization success and potential regulatory approvals.

The foregoing analysis synthesizes publicly disclosed financial results and strategic guidance from Beyond Air Inc. for fiscal 2026. All statements are based on available information and are subject to change with future developments.